Greenland Mines Ltd. (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory, and neurodegenerative diseases. The patent protects the use of the secreted Klotho ("s-KL") RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis ("ALS") and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.
This patent grant represents a significant milestone for Greenland Mines, as it strengthens the company's position in the rapidly evolving field of neurodegenerative disease treatments. The breadth of the patent claims suggests that the company may be able to secure a competitive advantage in developing therapies that modulate the s-KL protein, which has been linked to cognitive function and neuroprotection. With the aging global population, the market for effective treatments for Alzheimer's and Parkinson's diseases is substantial, and this intellectual property protection could be critical for future partnerships or commercialization.
For more details, the full press release is available at https://ibn.fm/x2pHA. The company also maintains a newsroom at https://ibn.fm/GRML for updates on GRML.
Greenland Mines operates two divisions: Mining and Biotech. The Mining division focuses on the Skaergaard Project in Greenland and the Sarfartoq rare earths project. The Biotech division includes Klotho's KLTO‑202 primary indication for ALS. The company's strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision.
Forward-looking statements in this article involve risks and uncertainties as described in the company's SEC filings. Investors should not place undue reliance on these statements.
